Psychopharmacotherapy in adolescents with borderline personality disorder in inpatient and outpatient psychiatric treatment;Psychopharmakotherapie einer ambulanten und stationären Inanspruchnahmepopulation adoleszenter Patienten mit Borderline- Persönlichkeitsstörung

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 38, Issue 1, 2010, Pages 37-49

  Wöckel, Lars ^a,b   Goth, Kirstin ^a   Matic, Nina ^a   Zepf, Florian Daniel ^a,b,c   Holtmann, Martin ^a,d   Poustka, Fritz ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c JARA TRANSLATIONAL BRAIN MEDICINE   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adolescence; Antidepressants; Borderline personality disorder; Neuroleptics; Psychopharmacotherapy

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; SERTRALINE;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ARTICLE; AUTOMUTILATION; BORDERLINE STATE; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATION; OUTPATIENT; PRESCRIPTION; PSYCHIATRIC TREATMENT; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SUICIDE ATTEMPT;

ADOLESCENT; AMBULATORY CARE; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BORDERLINE PERSONALITY DISORDER; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 74849128548     PISSN: 14224917     EISSN: None     Source Type: Journal    
DOI: 10.1024/1422-4917.a000005     Document Type: Article

References (65)

1. Akiskal, H. S., Chen, S. E., Davis, G. C., Puzantian, V. R., Kashgarian, M. & Bolinger, J.M. (1985). Borderline: An adjective in search of a noun. Journal of Clinical Psychiatry, 46, 41-48.
2. American Psychiatric Association (APA). (2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association.
3. American Psychiatric Association (APA). (2001). Practice guidelines for the treatment of patientswith borderline personality disorder. American Journal of Psychiatry, 158, 1-52.
4. American Psychiatric Association (APA). (2005). Psychopharmakotherapie und andere somatische Behandlungen. InH. Dilling (Ed.), Leitlinien zur Behandlung der Borderline Persönlichkeitsstörung. (1. Auflage; pp. 46-58&103-119). Bern: Huber.
5. Becker,D.F.,Grilo, C.M., Edell,W.S.&McGlashan, T.H. (2002). Diagnostic efficiency of borderline personality disorder criteria in hospitalized adolescents:Comparisonwith hospitalized adults. American Journal of Psychiatry, 159, 2042-2047.
6. Bellino, S., Zizza, M., Rinaldi, C.&Bogetto, F. (2006). Combined treatment of major depression in patients with borderline personality disorder: A comparison with pharmacotherapy. Canadian Journal of Psychiatry, 51, 453-460.
7. Bogenschutz,M. P. & Nurnberg, H. G. (2004). Olanzapine versus placebo in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 104-109.
8. Bohus, M. (2002). Pharmakotherapie. In D. Schulte, K. Grawe, K. Hahlweg & D. Vaitl (Hrsg.), Borderline-Störung, Fortschritte der Psychotherapie, Band 14 (1. Aufl., S. 121-122).
9. Göttingen: Hogrefe-Verlag. Braun-Scharm, H., Kieninger, S. &Wienecke, S. (2000). Persönlichkeitsstörungen im Jugendalter. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 28, 5-15.
10. Coid, J., Yang, M., Tyrer, P., Roberts, A. & Ullrich, S. (2006). Prevalence and correlates of personality disorder in Great Britain. British Journal of Psychiatry, 188, 423-431.
11. De la Fuente, J.M. & Lotstra, F. (1994). A trial of carbamazepine in borderline personality disorder. European Neuropsychopharmacology, 4, 479-486.
12. Fleischhaker, C., Munz, M., Böhme, R., Sixt, B. & Schulz, E. (2006). Dialektisch-Behaviorale Therapie für Adoleszente (DBT-A) - eine Pilotstudie zur Therapie von Suizidalität, Parasuizidalität und selbstverletzenden Verhaltensweisen bei Patientinnen mit Symptomen einer Borderlinestörung. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 34, 15-27.
13. Frankenburg, F. R. & Zanarini, M.C. (2002). Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. Journal of Clinical Psychiatry, 63, 442-446.
14. Gören, J. L. (2008). Antidepressants use in pediatric populations. Expert Opinion on Drug Safety, 7, 223-225.
15. Gunderson, J.G. (2005). Pharmakotherapie. In J. G. Gunderson (Hrsg.), Borderline. Diagnostik, Therapie, Forschung (1. Aufl., S. 153-182). Bern: Huber.
16. Gunderson, J. G., Weinberg, I., Daversa, M.T., Kueppenbender, K. D., Zanarini, M.C., Shea, M.T. et al. (2006). Descriptive and longitudinal observations on the relationship of borderline personality disorder and bipolar disorder. American Journal of Psychiatry, 163, 1173-1178.
17. Hammad, T. A., Laughren, T. & Racoosin, J. (2006). Suicidality in pediatric patients treated with antidepressant drugs. Archives of General Psychiatry, 63, 332-339.
18. Heinze, M., Andreae, D. & Grohmann, R. (2005). Pharmacotherapy of personality disorders in german speaking countries: State and changes in the last decade. Pharmacopsychiatry, 38, 201-205.
19. Herpertz, S. C., Zanarini, M., Schulz, C. S., Siever, L., Lieb, K., Möller, H.-L. et al. (2007). World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for biological treatment of personality disorders. The World Journal of Biological Psychiatry, 8, 212-244.
20. Hollander, E., Allen, A., Lopez, R. P., Bienstock, C. A., Grossman, R., Siever, L. J. et al. (2001). A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality. Journal of Clinical Psychiatry, 62, 199-203.
21. Hollander, E., Swann, A. C., Coccaro, E. F., Jiang, P. & Smith, T. B. (2005). Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. American Journal of Psychiatry, 162, 621-624.
22. Holtmann, M., Bölte, S. & Poustka, F. (2006). Suizidalität bei depressiven Kindern und Jugendlichen unter Behandlung mit selektiven Serotoninwiederaufnahmehemmern. Der Nervenarzt, 77, 1332-1337.
23. Internationale Klassifikation psychischer Störungen (ICD-10) der WHO. (2001). Spezifische Persönlichkeits- undVerhaltensstörungen. In H. Remschmidt, M. Schmidt & F. Poustka (Hrsg.), Multiaxiales Klassifikationsschema für psychische Störungen des Kindes- und Jugendalters (4. Aufl., S. 248-254). Bern: Huber.
24. Jobson, K.O. & Potter, W.Z. (1995). International Psychopharmacology Algorithm Project report. Psychopharmacology Bulletin, 31, 457-507.
25. Kölch, M. & Fegert, J. M. (2007). Medikamentöse Therapie der Depression bei Kindern und Jugendlichen. Praxis der Kinderpsychologie und Kinderpsychiatrie, 56, 224-233.
26. Krischer, M., Sevecke, K., Döpfner, M. & Lehmkuhl, G. (2006). Persönlichkeitsmerkmale im Kindes- und Jugendalter: Konzepte, methodische Ansätze und empirische Ergebnisse. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 34, 87-100.
27. Lieb, K., Zanarini, M.C., Schmahl, C., Linehan, M.M. & Bohus, M. (2004). Borderline personality disorder. Lancet, 364, 453-461.
28. Loew, T. H., Nickel, M.K. & Muehlbacher, M. (2006). Topiramate treatment for women with borderline personality disorder. Journal of Clinical Psychopharmacology, 26, 61-66.
29. Maier, W., Lichtermann, D., Klingler, T. & Heun, R. (1992). Pre-valences of personality disorders (DSM-III-R) in the community. Journal of Personality Disorders, 6, 187-196.
30. McGlashan, T. H. (1986). The Chestnut Lodge follow-up study; 3: Long-term outcome of borderline personalities. Archives of General Psychiatry, 43, 20-30.
31. Mobascher, A., Mobascher, J., Schmahl, C. & Malevani, J. (2007). Behandlung der Borderline-Persönlichkeitsstörung mit atypischen Antipsychotika. Der Nervenarzt, 78, 1003-1013.
32. National Institute for Clinical Excellence (NICE). (2005). Depression in children and young people identification and management in primary, community and secondary care. National Clinical Practice Guideline Number 28, developed by National Collaborating Centre for Mental Health commissioned by the National Institute for Clinical Excellence published by The British Psychological Society & The Royal College of Psychiatrists.
33. Nickel, M. K., Muehlbacher, M., Nickel, C., Kettler, C., Pedrosa Gil, F., Bachler, E. et al. (2006). Aripiprazole in the treatment of patients with borderline personality disorder: A double blind, placebo-controlled trial. American Journal of Psychiatry, 163, 833-838.
34. Nickel, M. K., Nickel, C., Kaplan, P., Lahmann, C., Muhlbacher, M., Tritt, K. et al. (2005). Treatment of aggression with topiramate in male borderline patients: A double-blind, placebocontrolled study. Biological Psychiatry, 57, 495-499.
35. Nickel, M. K., Nickel, C., Mitterlehner, F. O., Tritt, K., Lahmann, C., Leiberich, P. K. et al. (2004). Topiramate treatment of aggression in female borderline personality disorder patients: A double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 65, 1515-1519.
36. Nosè, M., Cpriani, A., Biancosino, B., Grassi, L. & Barbui, C. (2006). Efficacy of pharmacotherapy against core traits of borderline personality disorder: Meta-analysis of randomized controlled trials. International Clinical Psychopharmacology, 21, 345-353.
37. Paris, J. (2005a). Recent advances in the treatment of borderline personality disorder. Canadian Journal of Psychiatry, 50, 435-441.
38. Paris, J. (2005b). Outcome and epidemiological research on personality disorders: Implications for classification. Journal of Personality Disorders, 19, 557-562.
39. Philipsen, A., Limberger, M., Lieb, K., Feige, B., Kleindienst, N., Ebner-Priemer, U. et al. (2008). Attention deficit/hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. British Journal of Psychiatry, 192, 118-123.
40. Philipsen, A., Richter, H., Schmahl, C., Peters, J., Rüsch,N., Bohus, M. et al. (2004). Clonidine in acute aversive inner tension and self-injurious behavior in female patientswith borderline personality disorder. Journal of Clinical Psychiatry, 65, 1414-1419.
41. Philipsen, A., Schmahl, C. & Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196-199.
42. Pope, H. G., Jonas, J. M., Hudson, J. I., Cohen, B.M. & Gunderson, J. G. (1983). The validity of DSM-III borderline personality disorder. Archives of General Psychiatry, 40, 23-30.
43. Posey, D. J., Guenin, K. D., Kohn, A. E., Swiezy, N.B. &McDougle, C. J. (2001). A naturalistic open-label study of mirtazapine in autistic and other pervasive development disorders. Journal of Child and Adolescent Psychopharmacology, 11, 267-277.
44. Remmel, A. & Bohus, M. (2006). Pharmakologische und psychotherapeutische Behandlung der Borderline-Störung. Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 54, 185-197.
45. Rinne, T., van den Brink,W.,Wouters, L. & van Dyck, R. (2002). SSRI treatment of borderline personality disorder: A randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. American Journal of Psychiatry, 159, 2048-2054.
46. Salbach-Andrae, H., Bürger, A., Klinkowski, N., Lenz, K., Pfeiffer, E., Fydrich, T. et al. (2008). Diagnostik von Persönlichkeitsstörungen im Jugendalter nach SKID-II. Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie, 36, 117-125.
47. Salzman, C., Wolfson, A. N., Schatzberg, A., Looper, J., Henke, R., Albanese, M. et al. (1995). Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. Journal of Clinical Psychopharmacology, 15, 23-29.
48. Schmahl, C. & Bohus, M. (2001). Symptomorientierte Pharmakotherapie bei Borderline-Persönlichkeitsstörung. Fortschritte der Neurologie- Psychiatrie, 69, 310-321.
49. Schmeck, K. (2008). Konzeptuelle Fragen und Behandlungsansätze bei Persönlichkeitsstörungen im Jugendalter. Praxis der Kinderpsychologie und Kinderpsychiatrie, 57, 625-640.
50. Segal-Trivitz, Y., Bloch, Y., Goldburt, Y., Sobol-Havia, D., Levkovitch, Y. & Ratzoni, G. (2006). Comparison of symptoms and treatments of adults and adolescents with borderline personality disorder. International Journal of Adolescent Medicine and Health, 18, 215-220.
51. Senol, S., Dereboy, C. & Yuksel, N. (1997). Borderline disorder in Turkey: A 2- to 4-year follow-up. Social Psychiatry and Psychiatric Epidemiology, 32, 109-112.
52. Simpson, E. B., Yen, S., Costello, E., Rosen, K., Begin, A., Pistorello, J. et al. (2004). Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. Journal of Clinical Psychiatry, 65, 379-385.
53. Soler, J., Pascual, J. C., Campins, J., Barrachina, J., Puigdemont, D., Alvarez, E. et al. (2005). Double-blind, placebo-controlled study of dialectical behaviour therapy plus olanzapine for borderline personality disorder. American Journal of Psychiatry, 162, 1221-1224.
54. Soloff, P. (2000). Psychopharmacological treatment of borderline personality disorder. The Psychiatric Clinics of North America, 23, 169-192.
55. The Treatment for Adolescents with Depression Study (TADS) Team. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression treatment for adolescents with depression study (TADS) randomized controlled trial. Journal of the American Medical Association (JAMA), 292, 807-820.
56. The Treatment for Adolescents with Depression Study (TADS) Team. (2005). The treatment for adolescents with depression study (TADS): Demographic and clinical characteristics. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 28-40.
57. Tritt, K., Nickel, C., Lahmann, C., Leiberich, P. K., Rother, W., Loew, T.H. et al. (2005). Lamotrigine treatment of aggression in female borderline-patients: A randomized, double-blind, placebo-controlled study. Journal of Psychopharmacology, 19, 287-291.
58. Tsapakis, E.M., Soldani, F., Tondo, L. & Baldessarini, R. J. (2008). Efficacy of antidepressants in juvenile depression: Meta-analysis. The British Journal of Psychiatry, 193, 10-17.
59. Wewetzer, C., Herpertz, S.&Herpertz-Dahlmann, B. (2003). Persönlichkeitsstörungen. In DGKJPP, BAG & BKJPP (Hrsg.), Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (2. Auflage; S. 141-152). Köln: Deutscher Ärzte-Verlag.
60. Wewetzer, C., Herpertz, S., Herpertz-Dahlmann, B. & Oehler, K.-U. (2007). Persönlichkeitsstörungen. In DGKJPP, BAG & BKJPP (Hrsg.), Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter (3. Auflage; S. 141-152). Köln: Deutscher Ärzte-Verlag.
61. Zanarini, M.C. & Frankenburg, F. R. (2001). Olanzapine treatment of female borderline personality disorder patients:Adouble-blind, placebo-controlled pilot study. Journal of Clinical Psychiatry, 62, 849-854.
62. Zanarini, M.C. & Frankenburg, F. R. (2003). Omega-3-fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study. American Journal of Psychiatry, 160, 167-169.
63. Zanarini, M.C., Frankenburg, F. R., Hennen, J., Reich, D. B. & Silk, K. R. (2004). Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. American Journal of Psychiatry, 161, 2108-2114.
64. Zanarini, M.C., Frankenburg, F.R., Hennen, J. & Silk, K.R. (2004). Mental health service utilization by borderline personality disorder patients and Axis II comparison subjects followed prospectively for six years. Journal of Clinical Psychiatry, 65, 28-36.
65. Zanarini, M.C., Frankenburg, F. R. & Parachini, E. A. (2004). A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. Journal of Clinical Psychiatry, 65, 903-907.